Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 433

1.

Outcome predictors in cardiopulmonary resuscitation facilitated by extracorporeal membrane oxygenation.

Jung C, Janssen K, Kaluza M, Fuernau G, Poerner TC, Fritzenwanger M, Pfeifer R, Thiele H, Figulla HR.

Clin Res Cardiol. 2015 Aug 25. [Epub ahead of print]

PMID:
26303097
2.

Red cell distribution width and survival in patients hospitalized on a medical ICU.

Fujita B, Franz M, Figulla HR, Pfeifer R, Kabisch B, Fritzenwanger M, Jung C.

Clin Biochem. 2015 Jul 10. pii: S0009-9120(15)00272-6. doi: 10.1016/j.clinbiochem.2015.07.011. [Epub ahead of print]

PMID:
26169241
3.

[Interventions at the tricuspid valve : What is possible?].

Lauten A, Figulla HR.

Herz. 2015 Aug;40(5):759-64. doi: 10.1007/s00059-015-4332-1. German.

PMID:
26135466
4.

Targeted delivery of interleukin-10 to chronic cardiac allograft rejection using a human antibody specific to the extra domain A of fibronectin.

Franz M, Doll F, Grün K, Richter P, Köse N, Ziffels B, Schubert H, Figulla HR, Jung C, Gummert J, Renner A, Neri D, Berndt A.

Int J Cardiol. 2015 Sep 15;195:311-22. doi: 10.1016/j.ijcard.2015.05.144. Epub 2015 May 29.

PMID:
26056964
5.

Triple transcatheter and surgical valve replacement: a 'hybrid' approach to valvular heart disease.

Lauten A, Doenst T, Figulla HR.

Eur Heart J. 2015 Jun 3. pii: ehv241. [Epub ahead of print] No abstract available.

PMID:
26040802
6.

Decrease in circulating dendritic cell precursors in patients with peripheral artery disease.

Kretzschmar D, Rohm I, Schäller S, Betge S, Pistulli R, Atiskova Y, Figulla HR, Yilmaz A.

Mediators Inflamm. 2015;2015:450957. doi: 10.1155/2015/450957. Epub 2015 Apr 15.

7.

[Interventional therapy of heart valve diseases: future perspectives].

Figulla HR, Lauten A.

Herz. 2015 Apr;40(2):215-23. doi: 10.1007/s00059-015-4207-5. German.

PMID:
25822420
8.

Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial.

Thiele H, Schuler G, Neumann FJ, Hausleiter J, Olbrich HG, Schwarz B, Hennersdorf M, Empen K, Fuernau G, Desch S, de Waha S, Eitel I, Hambrecht R, Böhm M, Kurowski V, Lauer B, Minden HH, Figulla HR, Braun-Dullaeus RC, Strasser RH, Rochor K, Maier SK, Möllmann H, Schneider S, Ebelt H, Werdan K, Zeymer U; IABP-SHOCK II Trial Investigators.

Am Heart J. 2015 Apr;169(4):e7-8. doi: 10.1016/j.ahj.2015.01.009. Epub 2015 Jan 30. No abstract available.

PMID:
25819870
9.

Investigation of bacterial translocation in chronic ischemic heart failure in the rat.

Betge S, Stingl M, Pfister W, Figulla HR, Jung C.

Clin Lab. 2015;61(1-2):93-100.

PMID:
25807643
10.

QT variability improves risk stratification in patients with dilated cardiomyopathy.

Fischer C, Seeck A, Schroeder R, Goernig M, Schirdewan A, Figulla HR, Baumert M, Voss A.

Physiol Meas. 2015 Apr;36(4):699-713. doi: 10.1088/0967-3334/36/4/699. Epub 2015 Mar 23.

PMID:
25799313
11.

Intraaortic balloon counterpulsation and microcirculation in cardiogenic shock complicating myocardial infarction: an IABP-SHOCK II substudy.

Jung C, Fuernau G, de Waha S, Eitel I, Desch S, Schuler G, Figulla HR, Thiele H.

Clin Res Cardiol. 2015 Aug;104(8):679-87. doi: 10.1007/s00392-015-0833-4. Epub 2015 Feb 27.

PMID:
25720332
12.

Elevated plasma levels of interleukin-12p40 and interleukin-16 in overweight adolescents.

Lichtenauer M, Franz M, Fritzenwanger M, Figulla HR, Gerdes N, Jung C.

Biomed Res Int. 2015;2015:940910. doi: 10.1155/2015/940910. Epub 2015 Feb 2.

13.

Impairment of the endothelial glycocalyx in cardiogenic shock and its prognostic relevance.

Jung C, Fuernau G, Muench P, Desch S, Eitel I, Schuler G, Adams V, Figulla HR, Thiele H.

Shock. 2015 May;43(5):450-5. doi: 10.1097/SHK.0000000000000329.

PMID:
25692257
14.

Decreased regulatory T cells in vulnerable atherosclerotic lesions: imbalance between pro- and anti-inflammatory cells in atherosclerosis.

Rohm I, Atiskova Y, Drobnik S, Fritzenwanger M, Kretzschmar D, Pistulli R, Zanow J, Krönert T, Mall G, Figulla HR, Yilmaz A.

Mediators Inflamm. 2015;2015:364710. doi: 10.1155/2015/364710. Epub 2015 Jan 15.

15.

Percutaneous extracorporeal life support in patients with circulatory failure: results of the German Lifebridge Registry.

Jung C, Franz M, Figulla HR, Sonntag S, Hug M, Mudra H, Bauerschmitt R, Kleber FX, Feindt P, Mehlhorn U, Vahl C, Bruns HJ, Ferrari M.

J Invasive Cardiol. 2015 Feb;27(2):93-7.

16.

Decrease in circulating plasmacytoid dendritic cells during short-term systemic normobaric hypoxia.

Yilmaz A, Ratka J, Rohm I, Pistulli R, Goebel B, Asadi Y, Petri A, Kiehntopf M, Figulla HR, Jung C.

Eur J Clin Invest. 2015 Feb 4. doi: 10.1111/eci.12416. [Epub ahead of print]

PMID:
25652640
17.

Comparison of outcomes of patients with left ventricular ejection fractions ≤30% versus ≥30% having transcatheter aortic valve implantation (from the German Transcatheter Aortic Valve Interventions Registry).

Schaefer U, Zahn R, Abdel-Wahab M, Gerckens U, Linke A, Schneider S, Eggebrecht H, Sievert H, Figulla HR, Senges J, Kuck KH; German TAVI Registry.

Am J Cardiol. 2015 Mar 1;115(5):656-63. doi: 10.1016/j.amjcard.2014.12.019. Epub 2014 Dec 18.

PMID:
25613664
18.

Toxic Epidermal Necrolysis During Dronedarone Treatment: First Report of a Severe Serious Adverse Event Of A New Antiarrhythmic Drug.

Gecks T, Prochnau D, Franz M, Jung C, Kühnert H, Schliemann S, Figulla HR.

Cardiovasc Toxicol. 2015 Jan 15. [Epub ahead of print]

PMID:
25588686
19.

Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.

Franz M, Jung C, Lauten A, Figulla HR, Berndt A.

Cell Adh Migr. 2015;9(1-2):90-5. doi: 10.1080/19336918.2014.1000075.

PMID:
25562641
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk